Browse the evidence

When resistance profiles, elbow range of motion, and effort are matched, altering shoulder extension angle (neutral vs. maximally extended) does not produce meaningful differences in elbow flexor hypertrophy in untrained men.

For most recreational lifters, whether you perform bicep curls with your arms by your side (neutral) or slightly behind your torso (extended shoulder) makes no meaningful difference to muscle growth, provided you train to failure and manage the weight similarly. Choose the variation that feels best for your shoulders and allows you to lift consistently. Don't overcomplicate your exercise selection based on shoulder angle alone.

Supplementation with fish protein, vitamin D, and omega-3 fatty acids provides no additional benefit to physical performance adaptations (strength, endurance, workout duration) compared to whey protein or maltodextrin during a 6-week high-intensity functional training (HIFT) program in recreationally trained individuals.

If you are doing high-intensity functional training (like CrossFit), switching to a complex supplement with fish protein, vitamin D, and omega-3s will not give you better strength or endurance gains than taking whey protein or even just carbohydrates (maltodextrin), provided your overall diet is adequate. Focus on consistent training and basic protein intake rather than expensive multi-ingredient stacks for performance enhancement.

High body mass index (BMI ≥30 kg/m2) is a strong independent risk factor for the development and progression of Chronic Kidney Disease (CKD), primarily driven by compensatory glomerular hyperfiltration and increased intra-glomerular pressure.

Maintaining a healthy weight is one of the most effective ways to prevent kidney disease. Excess body weight forces your kidneys to work harder (hyperfiltration), which damages them over time. Focus on sustainable lifestyle changes like balanced nutrition and physical activity to lower your BMI, especially if you have central adiposity (large waist circumference), as this directly reduces the risk of developing chronic kidney disease.

Obesity causes chronic kidney disease through compensatory hyperfiltration and intraglomerular hypertension, leading to obesity-related glomerulopathy, independent of diabetes or hypertension.

High body weight increases pressure inside your kidneys (hyperfiltration), which damages them over time. This happens even if you don't have diabetes or high blood pressure. To protect your kidneys, focus on reducing visceral fat through diet and exercise, as this lowers the mechanical and hormonal stress on your kidney filters.

In individuals with ideal cardiovascular health (high CVHS), elevated BMI (≥35.0 kg/m²) does not significantly increase the risk of incident atherosclerotic cardiovascular disease (ASCVD) compared to normal BMI, whereas low cardiovascular health strongly predicts ASCVD regardless of BMI.

If you have ideal cardiovascular health (normal blood pressure, lipids, blood sugar, no smoking, active, healthy diet), your body weight (even if obese) may not significantly increase your risk of heart disease or stroke. Focus on maintaining these healthy habits rather than solely on weight loss.

Non-invasive mechanical ventilation (NIV) is superior to Continuous Positive Airway Pressure (CPAP) for treating Obesity Hypoventilation Syndrome (OHS) in patients without severe Obstructive Sleep Apnea (OSA), as CPAP fails to adequately correct daytime hypercapnia in this subgroup.

If you have Obesity Hypoventilation Syndrome but do not have severe sleep apnea, standard CPAP machines may not be enough to fix your high carbon dioxide levels. You likely need Non-Invasive Ventilation (NIV), which actively helps you breathe out more CO2. This is the standard of care for your specific profile.

Mandatory structured lifestyle modification programs prior to metabolic surgery do not improve post-operative outcomes and may cause harm by delaying access to surgery.

If you are being told you must complete a mandatory weight loss program before surgery, understand that this is likely a bureaucratic or insurance barrier, not a medical necessity. The evidence shows these programs do not improve surgical outcomes and may delay life-saving treatment. Seek a second opinion from a surgeon who follows modern guidelines that do not mandate pre-surgical weight loss.

SGLT2 inhibitors reduce the risk of hospitalization for heart failure and all-cause mortality in patients with type 2 diabetes compared to DPP-4 inhibitors.

If you have type 2 diabetes, ask your doctor about SGLT2 inhibitors (like empagliflozin). They are proven to lower the risk of heart failure hospitalization and death more effectively than DPP-4 inhibitors, offering significant cardiovascular protection beyond just blood sugar control.

Maternal obesity during the first trimester of pregnancy increases the risk of congenital heart defects and cardiovascular issues in offspring, mediated in part by maternal pregestational diabetes.

For women planning pregnancy, managing weight and blood sugar before conception is critical to protecting the child's long-term heart health. This is a preventative measure that starts before pregnancy.

Higher deficit accumulation frailty index (FI) scores are strongly associated with increased total health care costs, including medication, outpatient, and hospitalization expenses, in adults with type 2 diabetes and overweight/obesity.

For individuals with type 2 diabetes and obesity, monitoring for 'frailty' (defined as the accumulation of health deficits like blood pressure, mobility issues, and chronic conditions) is critical. Higher frailty scores predict significantly higher medical bills. Interventions that slow the progression of frailty, such as the intensive lifestyle intervention in this study, can lead to substantial annual savings in healthcare costs ($437-$461/year), primarily through reduced medication and hospitalization needs.

Lasting remission of type 2 diabetes is not feasible in real-world settings due to the progressive nature of the disease, lack of consensus on definitions, and high rates of weight regain and treatment discontinuation.

Do not expect type 2 diabetes to be 'cured' or stay in remission without ongoing effort. Biological mechanisms will push your body to regain weight and increase hunger. Focus on sustainable management rather than a one-time fix, and maintain regular monitoring of cardiovascular and microvascular health even if your glucose levels are normal.

GLP-1 agonists and bariatric surgery can achieve high rates of remission, but these are not true remission as they require ongoing treatment, and long-term sustainability is low without continuous intervention.

GLP-1 agonists and surgery are effective for achieving remission, but they are not cures. You will likely need to continue treatment or accept the risks of surgery. Discuss with your doctor whether the benefits of these interventions outweigh the need for ongoing management.

Among adults aged 50 and older with newly diagnosed type 2 diabetes, the prevalence of undiagnosed (silent) hypertension reaches 50%, significantly higher than in younger diabetic cohorts.

If you are over 50 and have just been diagnosed with type 2 diabetes, you have a 1 in 2 chance of having high blood pressure that you don't know about. Because you likely have no symptoms, you must get your blood pressure checked immediately at diagnosis to prevent long-term heart and kidney damage.

In older adults (≥50 years) with newly diagnosed type 2 diabetes, mean systolic blood pressure often remains below the clinical hypertension threshold (140 mmHg) despite a high prevalence of silent hypertension, indicating subclinical vascular changes.

If you are over 50 with type 2 diabetes, do not assume your blood pressure is safe just because it is under 140 mmHg. Your blood vessels may already be stiffening, and your risk for heart disease is high even without a formal hypertension diagnosis. Monitor your BP closely and manage other risk factors like cholesterol and weight.

Age, BMI, HbA1c, family history of hypertension, and waist circumference are independent predictors of silent hypertension in newly diagnosed type 2 diabetes patients.

Your risk of having undiagnosed high blood pressure when you get diabetes depends on your age, weight, blood sugar control, family history, and waist size. If you have these risk factors, you are more likely to have silent hypertension and should be screened aggressively.

SGLT2 inhibitors provide significant cardiovascular and renal protection in type 2 diabetes patients through mechanisms independent of glycemic control, including metabolic reprogramming and fuel switching.

If you have type 2 diabetes, ask your doctor about SGLT2 inhibitors. They protect your heart and kidneys through mechanisms beyond just lowering blood sugar, such as helping your body use different fuels. This can significantly reduce your risk of serious complications.

In patients with type 2 diabetes, the magnitude of weight loss achieved through semaglutide treatment (ranging from no loss to >10% loss) does not correlate with the risk of major adverse cardiovascular events (MACE), indicating that the drug's cardioprotective effects are independent of weight reduction.

If you are taking semaglutide for type 2 diabetes and cardiovascular risk, do not stop the medication if you are not losing as much weight as expected. The drug provides cardiovascular protection through direct effects on your blood vessels and heart, independent of how much weight you lose. Focus on the long-term heart health benefits rather than the number on the scale.

Postprandial glucose metabolism parameters derived from an Oral Glucose Tolerance Test (OGTT) do not predict anthropometric changes (weight, fat mass, or fat-free mass) following an 8-week low-calorie formula diet in adults with obesity.

If you are on a strict, low-calorie diet for 8 weeks, your body's specific glucose and insulin response to a sugar test (OGTT) will not help predict how much weight you will lose. The study found that baseline fat-free mass and sex were much better predictors of weight loss than metabolic phenotyping. Focus on adhering to the caloric deficit rather than seeking metabolic tests to guide short-term weight loss.

Conversional surgeries (e.g., RYGB, SADI-S, DS) are effective for managing post-bariatric recurrent weight gain (RWG) and diabetes recurrence, but carry higher risks of complications compared to primary surgery.

If you are gaining weight back after bariatric surgery and other treatments have failed, ask your doctor about conversional surgeries. These are more complex procedures that can effectively manage weight and diabetes, but they carry higher risks of complications. It is crucial to go to specialized centers with experienced surgeons and undergo strict postoperative surveillance.

Very low-carbohydrate diets (ketogenic) pose long-term sustainability, health, and environmental risks, including potential nutrient deficiencies and increased LDL cholesterol.

Be cautious with very low-carb diets. They can lead to nutrient deficiencies, increased LDL cholesterol, and are difficult to sustain long-term. Focus on balanced, high-quality diets instead.

Bariatric surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) provides long-term weight loss and high diabetes remission rates (51% at 12 years) by altering gut microbiota diversity and increasing specific beneficial bacteria like Bacteroides uniformis.

For severe obesity with type 2 diabetes, bariatric surgery (Roux-en-Y or Sleeve Gastrectomy) is the most effective long-term treatment, offering sustained weight loss (~35kg) and a 51% chance of diabetes remission after 12 years. This is achieved partly by reshaping the gut microbiome to favor beneficial bacteria.

Partially crystalline triacylglycerol droplets attenuate lipid digestion and bioaccessibility in vitro, but this effect does not necessarily translate to higher satiety or lower postprandial lipemia in humans compared to acid-stable liquid emulsions.

Don't assume that solid fats (like those in chocolate or certain cheeses) automatically digest slower or make you fuller than liquid fats. The stability of the fat emulsion in stomach acid is a critical factor for satiety that simple physical state doesn't capture.

High intake of linoleic acid (LA) does not impair the conversion of alpha-linolenic acid (ALA) to long-chain omega-3s (EPA/DHA) to a clinically significant degree, and the ratio of LA to ALA is less important than absolute intake levels.

You do not need to restrict seed oils to improve your omega-3 status. If you want more EPA/DHA, eat fish or algae supplements directly, as the body's conversion from plant sources (ALA) is inefficient regardless of how much seed oil you eat.

The observed 'obesity paradox' in diabetes is likely non-causal and explained by biases such as reverse causation, confounding by fitness, and body composition differences (muscle mass).

Do not interpret the 'obesity paradox' as a reason to gain weight. The survival advantage seen in obese diabetics is likely due to them having more muscle, being fitter, or having less severe disease at diagnosis, not the fat itself. Weight loss interventions are safe and recommended.